{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:25:10Z","timestamp":1767997510118,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T00:00:00Z","timestamp":1230076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00228-008-0600-9","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T13:35:23Z","timestamp":1230039323000},"page":"309-314","source":"Crossref","is-referenced-by-count":93,"title":["Persistence of antimuscarinic drug use"],"prefix":"10.1007","volume":"65","author":[{"given":"S\u00f8ren","family":"Brostr\u00f8m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,24]]},"reference":[{"key":"600_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol.Urodyn"},{"key":"600_CR2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766 (Erratum in: BJU Int 2001; 88:807)","journal-title":"BJU Int"},{"key":"600_CR3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","volume":"98","author":"SM Finney","year":"2006","unstructured":"Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions. BJU Int 98:503\u2013507","journal-title":"BJU Int"},{"key":"600_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","volume":"148","author":"P Abrams","year":"2006","unstructured":"Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565\u2013578","journal-title":"Br J Pharmacol"},{"key":"600_CR5","first-page":"CD003781","volume":"4","author":"G Nabi","year":"2006","unstructured":"Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4:CD003781","journal-title":"Cochrane Database Syst Rev"},{"key":"600_CR6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","volume":"20","author":"M Halaska","year":"2003","unstructured":"Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Bruhl B, Hofner K, Jonas U (2003) Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20:392\u2013399","journal-title":"World J Urol"},{"key":"600_CR7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","volume":"47","author":"F Haab","year":"2005","unstructured":"Haab F, Cardozo L, Chapple C, Ridder AM (2005) Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47:376\u2013384","journal-title":"Eur Urol"},{"key":"600_CR8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(02)00177-X","volume":"41","author":"K Kreder","year":"2002","unstructured":"Kreder K, Mayne C, Jonas U (2002) Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 41:588\u2013595","journal-title":"Eur Urol"},{"key":"600_CR9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1464-410X.2006.06439.x","volume":"98","author":"F Haab","year":"2006","unstructured":"Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD (2006) Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 98:1025\u20131032","journal-title":"BJU Int"},{"key":"600_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","volume":"8","author":"YF Yu","year":"2005","unstructured":"Yu YF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California Medicaid program. Value Health 8:495\u2013505","journal-title":"Value Health"},{"key":"600_CR11","first-page":"S121","volume":"11","author":"FT Shaya","year":"2005","unstructured":"Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Managed Care 11:S121\u2013S129","journal-title":"Am J Managed Care"},{"key":"600_CR12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1098-3015(10)62516-8","volume":"7","author":"MA Chui","year":"2004","unstructured":"Chui MA (2004) Patient persistence with medication for overactive bladder. Value Health 7:366","journal-title":"Value Health"},{"key":"600_CR13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1524-4733.2001.40202-243.x","volume":"4","author":"Z Zhou","year":"2001","unstructured":"Zhou Z, Barr C, Torigoe Y, Williamson T (2001) Persistence of therapy with drugs for overactive bladder. Value Health 4:161","journal-title":"Value Health"},{"key":"600_CR14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","volume":"104","author":"CJ Kelleher","year":"1997","unstructured":"Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988\u2013993","journal-title":"Br J Obstet Gynaecol"},{"key":"600_CR15","first-page":"5398","volume":"7","author":"EK Saks","year":"2006","unstructured":"Saks EK, Northington G, Gopal M, Arya L (2006) Adherence to anti-cholinergic medications in women with urge incontinence. Int Urogyn J 7:5398","journal-title":"Int Urogyn J"},{"key":"600_CR16","first-page":"445","volume":"44","author":"D Gaist","year":"1997","unstructured":"Gaist D, S\u00f8rensen HT, Hallas J (1997) The Danish prescription registers. Dan Med Bull 44:445\u2013448","journal-title":"Dan Med Bull"},{"key":"600_CR17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1742-7843.2006.pto_257.x","volume":"98","author":"J Hallas","year":"2006","unstructured":"Hallas J, Stovring H (2006) Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 98:260\u2013265","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"600_CR18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00001648-199711000-00013","volume":"8","author":"J Hallas","year":"1997","unstructured":"Hallas J, Gaist D, Bjerrum L (1997) The waiting-time distribution for prescription drugs. Epidemiology 8:666\u2013670","journal-title":"Epidemiology"},{"key":"600_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187\u2013220","journal-title":"J R Stat Soc B"},{"key":"600_CR20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.jhh.1001873","volume":"19","author":"C Bourgault","year":"2005","unstructured":"Bourgault C, S\u00e9n\u00e9cal M, Brisson M, Marentette MA, Gr\u00e9goire J-P (2005) Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Human Hypertens 19:607\u2013613","journal-title":"J Human Hypertens"},{"key":"600_CR21","unstructured":"Pesce F, Rubilotta E, D\u2019Amico A, Siracusano S, Righetti R, Celia A, Tiberio A, Artibani W (2003) Long-term anticholinergic therapy: duration and causes of discontinuation. Abstract 304 [poster]. International Continence Society 2003, 25\u201327 August 2003, Paris, France"},{"key":"600_CR22","first-page":"614","volume":"25","author":"L Brubaker","year":"2006","unstructured":"Brubaker L, Nichol M, Fanning K, Becker R, Jumadilova Z, Benner J (2006) Patient-reported reasons for discontinuing overactive bladder (OAB) medications. Neurourol Urodyn 25:614","journal-title":"Neurourol Urodyn"},{"key":"600_CR23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464\u2013470","journal-title":"Eur Urol"},{"key":"600_CR24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1098-3015(10)61180-1","volume":"5","author":"SJ Boccuzzi","year":"2002","unstructured":"Boccuzzi SJ, Le TK, Wogen J, Williamson T (2002) Utilization patterns associated with tolterodine immediate release versus oxybutinin in the management of urinary incontinence (UI). Value Health 5:274","journal-title":"Value Health"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-008-0600-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0600-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T10:26:02Z","timestamp":1738837562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0600-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,24]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0600-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,24]]}}}